Status: Recruiting
A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
Participants needed: 84
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Updated: Mar 3, 2026Locations: 5
Eligibility criteria
Subject must be 18 to 75 years of age inclusive, at the time of signing the info... [+7]
Subject is pregnant, lactating, or is planning to become pregnant during the stu... [+12]